IO Biotech Reveals Phase 3 Trial Results for Cylembio

IO Biotech ( (IOBT) ) has shared an announcement.

On August 11, 2025, IO Biotech announced the topline results from its Phase 3 trial of Cylembio in combination with pembrolizumab for treating advanced melanoma. The trial demonstrated an improvement in progression-free survival (PFS) with a median of 19.4 months compared to 11.0 months for pembrolizumab alone, although it narrowly missed statistical significance. The combination was well tolerated, with no new safety signals, and showed potential benefits across various subgroups, particularly in patients with PD-L1 negative tumors. IO Biotech plans to discuss these results with the FDA for a potential Biologics License Application and will present more detailed findings at an upcoming medical meeting.

The most recent analyst rating on (IOBT) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on IO Biotech stock, see the IOBT Stock Forecast page.

Spark’s Take on IOBT Stock

According to Spark, TipRanks’ AI Analyst, IOBT is a Neutral.

IO Biotech faces significant challenges due to its financial instability and lack of revenue. However, the progress in clinical trials and secured financing improve its future prospects, though it remains speculative. The technical analysis suggests neutral momentum, and the valuation highlights typical risks associated with biotech stocks awaiting commercialization.

To see Spark’s full report on IOBT stock, click here.

More about IO Biotech

IO Biotech operates in the biotechnology industry, focusing on developing immune-modulatory cancer vaccines. Its primary product, Cylembio, is an investigational therapeutic cancer vaccine aimed at treating advanced melanoma.

Average Trading Volume: 320,370

Technical Sentiment Signal: Buy

Current Market Cap: $119.2M

For an in-depth examination of IOBT stock, go to TipRanks’ Overview page.